Medical Management of Neurogenic Bladder for Children and Adults: A Review

Elizabeth Lucas, MD¹

¹Nationwide Children's Hospital, Columbus, Ohio

Neurogenic bladder is a chronic condition affecting patients of all ages with significant medical and quality of life implications. Goals of treatment consist of protection of the upper urinary tract and promotion of reliable urinary continence. Successful management involves medications and most often bladder drainage via clean intermittent catheterization. This article reviews current literature on medical management to achieve goals of treatment. **Key words:** catheterization, myelomeningocele, neurogenic bladder, spinal cord injury

Neurogenic bladder describes a variety of bladder dysfunction disorders that result from a lesion at any level in the central or peripheral nervous system. Among children, congenital neural tube defects (NTD), such as myelomeningocele, spinal dysraphism, or tethered cord lesions, are the most common causes. Older patients usually acquire the condition secondary to spinal cord injury (SCI), but it can also result from malignancies in the spinal column or neurological diseases like multiple sclerosis or Parkinson's disease. Importantly, neurogenic bladder is the source of significant morbidity, no matter what the etiology. Children with NTD have increased life expectancy owing to advancements in orthopedic and neurosurgical therapies. For virtually all these patients, neurogenic bladder sequelae account for many of their health care interactions and result in disruption of quality of life. Similarly, prior to neurogenic bladder intervention and management strategies, most SCI patients died of complications such as renal failure or urosepsis.¹ While no longer the main cause of mortality, more than 80% of SCI patients report at least one symptom of bladder dysfunction.² All cohorts of patients benefit from early evaluation and institution of appropriate treatment.³ Furthermore, cohorts share common goals of treatment: to minimize or prevent damage to the upper urinary tract and bladder and to maximize safe, social continence.

Pathophysiology of Neurogenic Bladder

To achieve urinary continence, the bladder must perform two functions: (1) store urine produced by the kidney, and (2) expel urine when appropriate. For success of both functions, neurological input is required from the cerebral cortex, spinal cord, and peripheral nervous system; disruption anywhere along those neural pathways can lead to various degrees of bladder dysfunction. For storage of urine, the muscles of the bladder are relaxed and the external sphincter contracted, and this is reversed when voiding is desired.⁴ The detrusor muscle, bladder neck, and striated external sphincter operate as a synergistic unit for these two tasks.⁴ Loss of coordination characterized by external sphincter contraction when detrusor muscles are also activated causes bladder outlet obstruction, a condition called *detrusor sphincter dyssynergia* (DSD). DSD incidence ranges from 20% to 50% among neurogenic bladder patients.⁵

The disordered interactions leading to neurogenic bladder are complex, diverse, and involve the multiple facets of the nervous system. A thorough discussion of all potential neurological disturbances would necessitate another review article. For readers who desire a more in-depth examination, Blok's chapter "Neuroanatomy Relevant to the Urologist" is an excellent resource.⁶

Corresponding author: Elizabeth Lucas, MD, Nationwide Children's Hospital, Complex Healthcare, Suite T1A, 700 Children's Drive, Columbus, OH 43205; phone: 614-722-5808; email: Elizabeth.lucas@nationwidechildrens.org

Top Spinal Cord Inj Rehabil 2019;25(3):195-204
© 2019 Thomas Land Publishers, Inc.
www.thomasland.com
doi: 10.1310/sci2503-195

Evaluation of Neurogenic Bladder

High-quality evidence guiding evaluation and follow-up for neurogenic bladder patients is lacking and based largely on expert opinion.⁷ Bauer et al advocated for urinary tract evaluation to begin shortly after neonates with myelomeningocele had repair of their defect and to occur at routine intervals or with any changes in symptomatology.⁸ These recommendations have been extrapolated to all infants with NTD or other neurological issues. The SCI literature offers less direction, and resolution of spinal shock is highly variable ranging from days to months post injury.⁹ Consequently, experts only strongly recommend undertaking a complete neurourological evaluation including urodynamic investigations within 3 months of the initial injury in both adults and children.^{10,11} However, Bywater et al demonstrated that a significant portion of early SCI patients had abnormal urodynamic parameters before 40 days post injury, and they advocated earlier targeted therapies to preserve upper and lower urinary tract function.¹² Children may experience a shorter duration of spinal shock as compared to adults, causing some experts to allow for evaluation earlier than 3 months.¹¹ Balancing against that recommendation, an early assessment may demonstrate poor parameters before bladder function has fully recovered, thus necessitating repeat invasive testing. Surgical interventions, irreversible by nature, should be delayed until after 1 year post-SCI to allow for the potential recovery of bladder function.¹⁰ In children, urodynamic studies should include measurement of bladder compliance and capacity, intravesical pressure, assessment of overactivity, and detrusor leak point pressure assessment.¹³ Prognostication among pediatric patients with neurogenic bladder can be divided into high- and low-risk cohorts based on intravesical pressure, with high-risk cohorts being defined by measurements greater than 40 cm H₂O.¹⁴ Patients with such measurements have poorer glomerular filtration rates, vesicoureteral reflux, upper urinary tract deterioration, more urinary tract infections, and hydronephrosis.¹⁵⁻¹⁷ Similarly, Kim et al reported that adults with SCI who had a bladder leak point pressure of 40 cm H₂O or greater had elevated rates of upper urinary tract damage and DSD.¹⁸

Nonsurgical Management of Neurogenic Bladder

Reflex voiding and bladder expression

Triggered reflex voiding is now a rarely used practice following the introduction of clean intermittent catheterization (CIC). However, it may still serve a role, especially in resource-poor areas. Triggered reflex voiding requires various maneuvers performed by the patient or caregiver to elicit an unphysiological sacral reflex to stimulate detrusor fibers in the bladder allowing voiding. Maneuvers are unique to each patient but examples include suprapubic tapping or jabbing, pulling on pubic hair, thigh scratching, touching the penile skin or clitoris, or ano-rectal manipulation.¹⁹ Bladder expression is another voiding technique that relies on applying a force to overcome outlet resistance of the external sphincter usually via the Valsalva (an individual increases intraabdominal pressure via breath-holding techniques) or Credé (increasing abdominal pressure through external manual pressure) maneuvers. These techniques are difficult to master, must only be tried in patients with confirmed safe urodynamic parameters, and have been associated with poor bladder emptying, subsequent hydronephrosis, and upper tract disease.²⁰ For these reasons and better documented outcomes with CIC, these techniques are no longer routinely recommended.

Condom catheter drainage

Condom catheters are an option for male neurogenic bladder patients who have incontinence or use reflex voiding/bladder expression. As a non-indwelling catheter, condom catheters may appear safe and to have lower rates of urinary tract infection (UTI), the most common catheter-associated infection. However, the external device can exert a tourniquet-like force on the penis, leading to devastating penile injury, edema, necrosis, urinary retention, hydronephrosis, and even death.²¹⁻²⁴ Regarding UTI rates in patients using condom catheters, the literature presents mixed results. Roth et al and Saint et al both reported lower rates of UTI compared to indwelling catheters users, Gao et al found higher rates, and

the Neurogenic Bladder Turkish Research Group found no significant effect on UTI rate.²⁵⁻²⁸ Thus condom catheter use warrants close monitoring in patients with cognitive or dementia issues, difficulty maintaining hygiene, abnormal sensory conditions, poor skin integrity, or retracted penis.

Intermittent bladder catheterization

Experts accept intermittent catheterization as the preferred method of bladder drainage for neurogenic bladder patient, even without high-quality randomized controlled trials directly comparing bladder drainage methods.²⁹ There are reports of this type of bladder emptying technique dating back to Roman and Egyptian eras, when reeds or silver tubes served as catheters.³⁰ Originally conceptualized as a “sterile” procedure, high costs and challenges with using this method in outpatients gave way to recommendations for “clean” catheterization in the landmark paper by Lapides in 1972.³¹ When used routinely, CIC effectively preserves kidney function by preventing overdistention of the bladder and reducing pressures, thereby promoting consistent blood flow to bladder walls.³² CIC improves continence among neurogenic bladder patients, facilitating greater community participation and decreasing home confinement. Patients have successfully learned to perform CIC as young as 4 years of age, allowing for their increased inclusion in mainstream education and improved quality of life.³³

Despite all its benefits, CIC does not come without compromises and chief among these is the acquisition of asymptomatic bacteriuria (ASB). ASB is defined as a positive urine culture from a patient who does not exhibit or complain of any urinary symptoms. In sensate patients this definition is apt; but among the SCI and NTD populations, sensation may be altered and symptoms cannot be reliably reported. Many excellent efforts by antimicrobial stewardship groups to curb inappropriate antibiotic use for ASB have been largely successful.³⁴⁻³⁶ However, patients with neurogenic bladder are often excluded from those guidelines, with the exception of the recommendation against routine screening for ASB in SCI.³⁶ The lack of inclusion of these patients in guidelines may be related to a failure

to develop a consistent definition of UTI versus ASB among neurogenic bladder patients leading to difficulties comparing literature.³⁷ This in turn leads to significant heterogeneity of evaluation and management of these patients even among urologists.³⁸ Antibiotic prophylaxis has been shown to reduce ASB in neurogenic bladder patients, but it does not reduce symptomatic UTIs.³⁹ The exception to that statement is pregnant females who perform CIC, in which case, prophylactic antibiotics are associated with fewer symptomatic UTIs.⁴⁰

UTIs present another clinical challenge associated with CIC use. Uropathogens interact with catheter surfaces, and the act of catheterization provides these pathogens direct access to the urinary tract.⁴¹ Frequency of CIC is dictated by fluid intake and urodynamic parameters, but most patients require the procedure 4 to 6 times per day. Catheterization performed less often is a risk factor for UTI development, stemming from bladder overdistention.⁴² To prevent UTIs, it is important to educate patients on routine use of CIC, avoidance of bladder overfilling, and careful hygiene.²⁹ Catheters of alternative materials, including hydrophilic catheters, those impregnated with antimicrobial materials, and chlorhexidine-coated catheters, have been proposed as another preventative measure demonstrating some promising results.⁴³⁻⁴⁷

Less common complications associated with CIC are mechanical issues related to repeatedly performing the procedure. Lesions can occur from damage to the urethral mucosa causing stricture, bleeding, leaking, or the development of false tracts. In pediatric patients, catheterizable channel complications require revision at a rate of 25% to 30%. Interestingly, patients older than 21 when their channel is surgically created have higher revision rates, ranging between 31% to 54%.⁴⁸

Indwelling catheters

Indwelling urethral catheters

Placement of an indwelling urethral catheter (IUC) is a common practice for patients in the acute stage following an SCI, allowing for close monitoring of a patient's fluid balance. IUCs must

be inserted under sterile conditions, and they are worn continuously. While there are advantages with a single insertion and continuous bladder drainage, IUCs are associated with higher rates of cystitis and pyelonephritis as compared to CIC.⁴⁹⁻⁵² Acquisition of bacteriuria occurs at a rate of 3% to 8% for each day an IUC remains in place, and length of IUC placement is the main risk factor for conversion to an UTI.⁵³ Furthermore, IUCs cause a greater risk of urethral erosion, development of urethral stricture, upper urinary tract deterioration, kidney stones, or infectious complications such as epididymitis and urethral abscess.²⁹ IUC should be reserved for circumstances in which patients are unable to perform CIC or during defined periods of time when careful fluid balance is necessary.

Suprapubic catheters

Suprapubic catheters (SPC) can be placed in a surgically created channel for common indications such as persistent incontinence despite CIC, inability to perform CIC, channel stricture or other damage, or progression of neurological disease.⁵⁴ Some distinctive benefits of indwelling catheter placement via an SPC include improved independence by reduced need to perform catheterization multiple times per day, improved body image, and sexual function.^{55,56} SPC users experience higher rates of UTI and nephrolithiasis as compared to their CIC counterparts who do not have an indwelling foreign body, but rates of urosepsis, epididymitis, and pyelonephritis are comparable.⁵⁷

Pharmacological management of neurogenic bladder

Alpha-blocker medications

In the sphincter and bladder neck muscles, activation of α_1 -adrenergic receptors results in sphincter mechanism tension and inactivation of those receptors allows for voiding. In patients with increased sphincter activity, overfilling of the bladder leads to elevated intravesicular pressures. In these patients, α -blockers are used to reduce the sphincter tension to facilitate voiding, thereby reducing incontinence episodes and decreasing catheterization frequency.⁵⁸ In adults with SCI or multiple sclerosis, use of α -blockers

improves postvoid residuals, increases urine flow rates, improves autonomic dysreflexia, and decreases detrusor overactivity.^{59,60} α -Blockers prescribed in children have shown some decrease in bladder outlet resistance, but only in a small numbers of patients because this use is off-label.⁶¹ Formulations of α -blockers available include alfuzosin, tamsulosin, and doxazosin. Side-effect profiles for these medications include drowsiness and decreased blood pressure, which may be more significant among pediatric patients.⁶¹

Anticholinergic medications

Anticholinergic medications are typically considered first-line therapy for neurogenic bladder patients. They act on muscarinic receptors in the bladder to reduce the contraction of the detrusor muscles, especially during the storage phase. Their use in patients with detrusor overactivity demonstrates reduced intravesicular pressure and increased bladder capacity during the storage phase and decreased episodes of leaking, incontinence, and frequency voiding.^{62,63} Oxybutynin has been prescribed since the 1970s, so it has the most data supporting its use; it is available in oral, transdermal, and intravesical instillation solution formulations. Other anticholinergic drugs include tolterodine, propiverine, trospium, solifenacin, darifenacin, and fesoterodine, which having varying levels of selectivity among muscarinic receptors. Oxybutynin and tolterodine have US Food and Drug Administration (FDA) approval for use in children older than 5 years of age.⁶⁴ Muscarinic receptors are widely distributed in the body, so potential side effects range from blurry vision, cognitive impairment, dry mouth, gastroesophageal reflux, constipation, and urinary retention. Children generally tolerate these side effects better than adults, but they can be cause for discontinuation.^{65,66} There is insufficient evidence to recommend one anticholinergic medication over another, but some pediatric trials are pending among the more selective medications such as solifenacin.^{62,64}

Botulinum neurotoxin

Botulinum toxin is produced by the facultative anaerobic bacteria *Clostridium botulinum*. When

injected in the detrusor muscle, it inhibits the release of acetylcholine achieving an effect analogous to that of anticholinergic medications.⁶⁷ For patients intolerant or refractory to the previously presented oral medications, botulinum toxin may be a good alternative. In children, injection effectively increased bladder capacity and decreased intravesical pressure with overall improvement in continence.⁶⁸⁻⁷⁰ Children tolerate multiple injections and effects last for 6-9 months, much longer than when botulinum toxin is injected into skeletal muscle.^{69,71-74} Application drawbacks specific to pediatric patients relate to the requirement of general anesthesia for the procedure, but otherwise, few side effects are reported.⁷⁵ A few small case series evaluated intravesical instillation of botulinum toxin without general anesthesia and reported good clinical results, but participants also experienced adverse events of urinary retention, injection site pain, UTIs, and hematuria.⁷⁶⁻⁷⁸ Drug delivery alternatives have been developed, and a small case series of myelomeningocele patients with resistant detrusor dysfunction used an electromotive drug administration of botulinum toxin intravesically. Six years after follow-up, these patients still experienced improved continence and decreased detrusor pressure. This drug delivery method does not require anesthesia, can be performed in the outpatient clinic, and is painless for pediatric patients.⁷⁹

In adult patients with SCI or multiple sclerosis, botulinum toxin is reserved for detrusor muscle inhibition refractory to oral anticholinergic medications or when such medications are not tolerated due to their side effects.⁸⁰⁻⁸⁸ Well-designed trials with randomization and placebo control document improved urodynamic parameters and quality of life measures among adults with neurogenic bladder dysfunction and detrusor overactivity.⁸⁹⁻⁹⁴ UTI is the most common adverse event, and urinary retention or incomplete bladder emptying is reported with botulinum toxin dose escalation. Kennelly et al presented a long-term study with 4-year follow-up of patients receiving multiple injections of botulinum toxin, describing that effects last a median time of 9 months. Adverse events included UTIs and incomplete bladder emptying. The authors also sought to address

potential concerns about the development of antibodies in response to botulinum toxin use, a phenomenon reported in patients receiving injections into the large skeletal muscles of the neck, but detection levels were low and half of those patients continued to report clinical benefit despite seroconversion.⁹⁵

Alternative medications for neurogenic bladder management

Mirabegron is a β_3 -adrenoceptor agonist that acts to relax the detrusor smooth muscle during the storage phase. As a non-anticholinergic bladder relaxant, mirabegron has a more desirable side-effect profile than anticholinergics, but there is more limited evidence to support its use.²⁴ Trials in children with a small number of participants showed increased bladder capacity and decreased incontinence.⁶⁴ Probiotics are another therapy with the potential to support neurogenic bladder patients. A Cochrane review looked for studies using probiotics as a UTI prevention strategy for patients with neurogenic bladder and turned up very little evidence. There were no studies identified that evaluated oral probiotics effects, but there were three studies looking at intravesical instillation of nonpathogenic strains of *E. coli*. These studies included only 110 patients overall. Authors concluded that while there is likely to be minimal harm from these methods, there is insufficient evidence to support their use at this time.⁹⁶

Future Directions

Normal bladder storage and voiding occur through a complex interplay of multiple neurological systems. Preclinical trials and even a few human trials have looked at electrical stimulation at various targets in SCI patients utilizing physiological neural control mechanisms. One small case series demonstrated preservation of bladder compliance, decreased detrusor overactivity, and improved bowel and erectile function in SCI patients who were introduced to early sacral neuromodulation.⁹⁷ Another case series followed SCI patients after a program of repeated electrical stimulation treatments. Those patients had increased bladder capacity, improved bladder

emptying, and lower intravesical pressure at 2-year follow-up.⁹⁸ Techniques that show promising results include pudendal nerve stimulation and high-frequency nerve stimulation for bladder control.⁹⁹ Randomized trials for implanted devices that stimulate the neurogenic bladder are ongoing and may present another alternative to permanent surgery interventions.¹⁰⁰

Transitions of Care: An Important Crossroads for Patients and Caregivers

Improved life expectancy has created a new challenge for patients with neurodevelopmental disorders and their caregivers — navigation of the transition from child-centered to adult-centered medical care. Fragmented care is estimated to cause one-third of hospitalizations among adults with myelomeningocele for admissions considered preventable, and even academic centers with a well-established multidisciplinary clinic fail to do this well.¹⁰¹⁻¹⁰³ A likely multifactorial problem, patients cite hesitancy to leave pediatric providers, insurance coverage issues, unreliable transportation, health care fatigue, and communication difficulties as barriers.^{104,105} For their part, pediatric practitioners can fail to release their patients to adult providers

in a timely manner, and adult providers may be disinterested or feel inadequately trained to care for special needs populations.¹⁰⁶ Tools have been validated for assessing readiness for transition, and these may assist providers by identifying barriers prior to attempting transition.¹⁰⁷⁻¹⁰⁹ Anecdotally, I believe there is no substitute for deliberate and repeated communication between pediatric providers, patients, and their caregivers and with preselected adult providers to promote successful transition.

Conclusion

Medical management for adults and children with neurogenic bladder generally follows similar principles, and the goals of treatment remain the same — minimize damage and deterioration of the upper urinary tract and maximize quality of life. Clinicians have a variety of medications and mechanical maneuvers to optimize and personalize treatment of patients with neurogenic bladder. No one therapy is definitive, and often combinations of treatments are used to manage this lifelong condition. The future holds potential for more targeted drug therapies and new technologies directed at ameliorating disordered neurological patterns that lead to neurogenic bladder.

REFERENCES

1. Hackler RH. A 25-year prospective mortality study in the spinal cord injured patient: Comparison with the long-term living paraplegic. *J Urol*. 1977;117:486-488.
2. Ku JH. The management of neurogenic bladder and quality of life in spinal cord injury. *BJU Int*. 2006;98:739-745.
3. Costa Monteiro LM, Cruz GO, Fontes JM, et al. Early treatment improves urodynamic prognosis in neurogenic voiding dysfunction: 20 years of experience. *J Pediatr (Rio J)*. 2017;93:420-427.
4. Dmochowski R. *Neuro-urology*. New York, NY: Springer Berlin Heidelberg; 2018.
5. Stoffel JT. Detrusor sphincter dyssynergia: A review of physiology, diagnosis, and treatment strategies. *Transl Androl Urol*. 2016;5:127-135.
6. Blok B. Neuroanatomy relevant for the urologist. In: Dmochowski R, ed. *Neuro-Urology*. Cham, Switzerland: Springer International; 2018:3-12.
7. Averbeck MA, Madersbacher H. Follow-up of the neuro-urological patient: A systematic review. *BJU Int*. 2015;115(Suppl 6):39-46.
8. Bauer SB, Hallett M, Khoshbin S, et al. Predictive value of urodynamic evaluation in newborns with myelodysplasia. *JAMA*. 1984;252:650-652.
9. Ditunno JF, Little JW, Tessler A, Burns AS. Spinal shock revisited: A four-phase model. *Spinal Cord*. 2004;42:383-395.
10. Welk B, Schneider MP, Thavaseelan J, Traini LR, Curt A, Kessler TM. Early urological care of patients with spinal cord injury. *World J Urol*. 2018;36:1537-1544.
11. Eswara JR, Castellan M, Gonzalez R, Mendieta N, Cendron M. The urological management of children with spinal cord injury. *World J Urol*. 2018;36:1593-1601.
12. Bywater M, Tornic J, Mehnert U, Kessler TM. Detrusor acontractility after acute spinal cord injury-myth or reality? *J Urol*. 2018;199:1565-1570.
13. Bauer SB, Nijman RJ, Drzewiecki BA, Sillen U, Hoebeke P, International Children's Continence Society Standardization S. International Children's Continence Society standardization report on urodynamic studies of the lower urinary tract in children. *Neurourol Urodyn*. 2015;34:640-647.

14. Hopps CV, Kropp KA. Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. *J Urol.* 2003;169:305-308.
15. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. *J Urol.* 1981;126:205-209.
16. Steinhardt GF, Goodgold HM, Samuels LD. The effect of intravesical pressure on glomerular filtration rate in patients with myelomeningocele. *J Urol.* 1988;140:1293-1295.
17. Wang SC, McGuire EJ, Bloom DA. A bladder pressure management system for myelodysplasia-clinical outcome. *J Urol.* 1988;140:1499-1502.
18. Kim YH, Kattan MW, Boone TB. Bladder leak point pressure: The measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia. *J Urol.* 1998;159:493-496; discussion 6-7.
19. Cardenas DD, Kelly E, Mayo ME. Manual stimulation of reflex voiding after spinal cord injury. *Arch Phys Med Rehabil.* 1985;66:459-462.
20. Wyndaele JJ, Madersbacher H, Kovindha A. Conservative treatment of the neuropathic bladder in spinal cord injured patients. *Spinal Cord.* 2001;39:294-300.
21. Kawoosa NU. Isolated gangrene of the penis in a paraplegic patient secondary to a condom catheter. *Indian J Surg.* 2011;73:30430-6.
22. Jabbour Y, Abdoulazizi B, Karmouni T, El Khader K, Koutani A, Iben Attya Andalousi A. Penile gangrene and necrosis leading to death secondary to strangulation by condom catheter. *Case Rep Urol.* 2018;2018:3702412.
23. Pidde TJ, Little JW. Hydronephrosis due to improper condom catheter use. *J Am Paraplegia Soc.* 1994;17:168-170.
24. Vaidyanathan S, Selmi F, Hughes PL, Singh G, Soni BM. Urinary retention and acute kidney injury in a tetraplegic patient using condom catheter after partying: A preventable complication. *Int Med Case Rep J.* 2015;8:241-245.
25. Roth JD, Pariser JJ, Stoffel JT, et al. Patient subjective assessment of urinary tract infection frequency and severity is associated with bladder management method in spinal cord injury [published online ahead of print March 14, 2019]. *Spinal Cord.*
26. Saint S, Kaufman SR, Rogers MA, Baker PD, Ossenkop K, Lipsky BA. Condom versus indwelling urinary catheters: A randomized trial. *J Am Geriatr Soc.* 2006;54:1055-1061.
27. Gao Y, Danforth T, Ginsberg DA. Urologic management and complications in spinal cord injury patients: A 40- to 50-year follow-up study. *Urology.* 2017;104:52-58.
28. Neurogenic Bladder Turkish Research Group, Yildiz N, Akkoc Y, et al. Neurogenic bladder in patients with traumatic spinal cord injury: Treatment and follow-up. *Spinal Cord.* 2014;52:462-467.
29. Romo PGB, Smith CP, Cox A, et al. Non-surgical urologic management of neurogenic bladder after spinal cord injury. *World J Urol.* 2018;36:1555-1568.
30. Bray L, Sanders C. Teaching children and young people intermittent self-catheterization. *Urol Nurs.* 2007;27:203-209, 42.
31. Lapidès J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. *J Urol.* 1972;107:458-461.
32. Lamin E, Newman DK. Clean intermittent catheterization revisited. *Int Urol Nephrol.* 2016;48:931-939.
33. Oakeshott P, Hunt GM. Intermittent self catheterization for patients with urinary incontinence or difficulty emptying the bladder. *Br J Gen Pract.* 1992;42:253-255.
34. Trautner BW, Grigoryan L, Petersen NJ, et al. Effectiveness of an antimicrobial stewardship approach for urinary catheter-associated asymptomatic bacteriuria. *JAMA Intern Med.* 2015;175:1120-1127.
35. Zabarsky TF, Sethi AK, Donskey CJ. Sustained reduction in inappropriate treatment of asymptomatic bacteriuria in a long-term care facility through an educational intervention. *Am J Infect Control.* 2008;36:476-480.
36. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America [published online ahead of print March 21, 2019]. *Clin Infect Dis.*
37. Madden-Fuentes RJ, McNamara ER, Lloyd JC, et al. Variation in definitions of urinary tract infections in spina bifida patients: A systematic review. *Pediatrics.* 2013;132:132-139.
38. Elliott SP, Villar R, Duncan B. Bacteriuria management and urological evaluation of patients with spina bifida and neurogenic bladder: A multicenter survey. *J Urol.* 2005;173:217-220.
39. Vickrey BG, Shekelle P, Morton S, Clark K, Pathak M, Kamberg C. Prevention and management of urinary tract infections in paralyzed persons. *Evid Rep Technol Assess (Summ).* 1999:1-3.
40. Michau A, Dinh A, Denys P, et al. Control cross-sectional study evaluating an antibiotic prevention strategy in 30 pregnancies under clean intermittent self-catheterization and review of literature. *Urology.* 2016;91:58-63.
41. Wyndaele JJ, Brauner A, Geerlings SE, Bela K, Peter T, Bjerklund-Johanson TE. Clean intermittent catheterization and urinary tract infection: Review and guide for future research. *BJU Int.* 2012;110:E910-917.
42. Bakke A, Digraanes A, Hoisaeter PA. Physical predictors of infection in patients treated with clean intermittent catheterization: A prospective 7-year study. *Br J Urol.* 1997;79:85-90.
43. Sutherland RS, Kogan BA, Baskin LS, Mevorach RA. Clean intermittent catheterization in boys using the LoFric catheter. *J Urol.* 1996;156:2041-2043.
44. De Ridder DJ, Everaert K, Fernandez LG, et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: A prospective randomised parallel comparative trial. *Eur Urol.* 2005;48:991-995.

45. Stensballe J, Looms D, Nielsen PN, Tvede M. Hydrophilic-coated catheters for intermittent catheterisation reduce urethral micro trauma: A prospective, randomised, participant-blinded, crossover study of three different types of catheters. *Eur Urol*. 2005;48:978-983.
46. Tenke P, Koves B, Johansen TE. An update on prevention and treatment of catheter-associated urinary tract infections. *Curr Opin Infect Dis*. 2014;27:102-107.
47. Lucas EJ, Baxter C, Singh C, et al. Comparison of the microbiological milieu of patients randomized to either hydrophilic or conventional PVC catheters for clean intermittent catheterization. *J Pediatr Urol*. 2016;12:172 e1-8.
48. Hampson LA, Baradaran N, Elliott SP. Long-term complications of continent catheterizable channels: A problem for transitional urologists. *Transl Androl Urol*. 2018;7:558-566.
49. Shekelle PG, Morton SC, Clark KA, Pathak M, Vickrey BG. Systematic review of risk factors for urinary tract infection in adults with spinal cord dysfunction. *J Spinal Cord Med*. 1999;22:258-272.
50. Jahromi MS, Mure A, Gomez CS. UTIs in patients with neurogenic bladder. *Curr Urol Rep*. 2014;15:433.
51. Bonfill X, Rigau D, Esteban-Fuertes M, et al. Efficacy and safety of urinary catheters with silver alloy coating in patients with spinal cord injury: A multicentric pragmatic randomized controlled trial. The ESCALE trial. *Spine J*. 2017;17:1650-1657.
52. Garcia-Arguello LY, O'Horo JC, Farrell A, et al. Infections in the spinal cord-injured population: A systematic review. *Spinal Cord*. 2017;55:526-534.
53. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50:625-663.
54. Nomura S, Ishido T, Teranishi J, Makiyama K. Long-term analysis of suprapubic cystostomy drainage in patients with neurogenic bladder. *Urol Int*. 2000;65:185-189.
55. Moreno JG, Chancellor MB, Karasick S, King S, Abdill CK, Rivas DA. Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. *Arch Phys Med Rehabil*. 1995;76:758-762.
56. Hess MJ, Hough S. Impact of spinal cord injury on sexuality: Broad-based clinical practice intervention and practical application. *J Spinal Cord Med*. 2012;35:211-218.
57. Sugimura T, Arnold E, English S, Moore J. Chronic suprapubic catheterization in the management of patients with spinal cord injuries: Analysis of upper and lower urinary tract complications. *BJU Int*. 2008;101:1396-1400.
58. Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. *Spinal Cord*. 2016;54:78-82.
59. Chancellor MB, Erhard MJ, Hirsch IH, Stass WE, Jr. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. *J Urol*. 1994;151:111-113.
60. Kakizaki H, Ameda K, Kobayashi S, Tanaka H, Shibata T, Koyanagi T. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. *Int J Urol*. 2003;10:576-581.
61. Kroll P, Gajewska E, Zachwieja J, Sobieska M, Mankowski P. An evaluation of the efficacy of selective alpha-blockers in the treatment of children with neurogenic bladder dysfunction—preliminary findings. *Int J Environ Res Public Health*. 2016;13.
62. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: A systematic review and meta-analysis. *Eur Urol*. 2012;62:816-830.
63. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. *Cochrane Database Syst Rev*. 2006:CD003781.
64. Kroll P. Pharmacotherapy for pediatric neurogenic bladder. *Paediatr Drugs*. 2017;19:463-478.
65. Ferrara P, D'Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. *BJU Int*. 2001;87:674-678.
66. Blais AS, Bergeron M, Nadeau G, Ramsay S, Bolduc S. Anticholinergic use in children: Persistence and patterns of therapy. *Can Urol Assoc J*. 2016;10:137-140.
67. Hsieh PF, Chiu HC, Chen KC, Chang CH, Chou EC. Botulinum toxin A for the treatment of overactive bladder. *Toxins (Basel)*. 2016;8.
68. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. *Eur Urol*. 2003;44:139-143.
69. Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. *J Urol*. 2006;175:1102-1105.
70. Ingham J, Angotti R, Lewis M, Goyal A. Onabotulinum toxin A in children with refractory idiopathic overactive bladder: Medium-term outcomes. *J Pediatr Urol*. 2019;15:32 e1-e5.
71. Horst M, Weber DM, Bodmer C, Gobet R. Repeated botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. *Neurourol Urodyn*. 2011;30:1546-1549.
72. Le Nue R, Harper L, De Seze M, Bouteiller C, Goossens D, Dobremez E. Evolution of the management of acquired neurogenic bladder in children using intradetrusor botulinum toxin type A injections: 5-year experience and perspectives. *J Pediatr Urol*. 2012;8:497-503.
73. Sager C, Burek C, Bortagaray J, et al. Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder. *Pediatr Surg Int*. 2014;30:79-85.

74. Sekerci CA, Tanidir Y, Garayev A, Akbal C, Tarcan T, Simsek F. Clinical and urodynamic results of repeated intradetrusor onabotulinum toxin A injections in refractory neurogenic detrusor overactivity: Up to 5 injections in a cohort of children with myelodysplasia. *Urology*. 2018;111:168-175.
75. Scheepe JR, Blok BF, 't Hoen LA. Applicability of botulinum toxin type A in paediatric neurogenic bladder management. *Curr Opin Urol*. 2017;27:14-19.
76. Krhut J, Zvara P. Intravesical instillation of botulinum toxin A: An in vivo murine study and pilot clinical trial. *Int Urol Nephrol*. 2011;43:337-343.
77. Do Ngoc Thanh C, Audry G, Forin V. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: A retrospective study of seven cases. *J Pediatr Urol*. 2009;5:430-436.
78. Blackburn SC, Jones C, Bedoya S, Steinbrecher HA, Malone PS, Griffin SJ. Intravesical botulinum type-A toxin (Dysport[®]) in the treatment of idiopathic detrusor overactivity in children. *J Pediatr Urol*. 2013;9:750-753.
79. Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM. Intravesical electromotive botulinum toxin type "A" administration for management of urinary incontinence secondary to neuropathic detrusor overactivity in children: Long-term follow-up. *Urology*. 2018;114:167-174.
80. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. *J Urol*. 2000;164:692-697.
81. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. *Eur Urol*. 2004;45:510-515.
82. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? *Neurourol Urodyn*. 2005;24:231-236.
83. Klaphajone J, Kitisomprayoonkul W, Sriplakit S. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. *Arch Phys Med Rehabil*. 2005;86:2114-2118.
84. Hajebrahimi S, Altaweel W, Cadoret J, Cohen E, Corcos J. Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: Initial results. *Can J Urol*. 2005;12:2543-2546.
85. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. *J Urol*. 2005;174:984-989.
86. Stohrer M, Wolff A, Kramer G, et al. Treatment of neurogenic detrusor overactivity with botulinum toxin A: The first seven years. *Urol Int*. 2009;83:379-385.
87. Wefer B, Ehlken B, Bremer J, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. *World J Urol*. 2010;28:385-390.
88. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: A prospective randomized study. *J Urol*. 2004;172:240-243.
89. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. *J Urol*. 2005;174:196-200.
90. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomised, placebo-controlled, double-blind study. *Scand J Urol Nephrol*. 2007;41:335-340.
91. Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial. *J Urol*. 2011;185:2229-2235.
92. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. *Eur Urol*. 2011;60:742-750.
93. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. *J Urol*. 2012;187:2131-2139.
94. Apostolidis A, Thompson C, Yan X, Mourad S. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. *World J Urol*. 2013;31:1469-1474.
95. Kennelly M, Dmochowski R, Schulte-Baukloh H, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. *Neurourol Urodyn*. 2017;36:368-375.
96. Toh SL, Boswell-Ruys CL, Lee BSB, Simpson JM, Clezy KR. Probiotics for preventing urinary tract infection in people with neuropathic bladder. *Cochrane Database Syst Rev*. 2017;9:CD010723.
97. Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. *Ann Neurol*. 2010;67:74-84.
98. Radziszewski K. Outcomes of electrical stimulation of the neurogenic bladder: Results of a two-year follow-up study. *NeuroRehabilitation*. 2013;32:867-873.
99. McGee MJ, Amundsen CL, Grill WM. Electrical stimulation for the treatment of lower urinary tract dysfunction after spinal cord injury. *J Spinal Cord Med*. 2015;38:135-146.
100. Redshaw JD, Lenherr SM, Elliott SP, et al. Protocol for a randomized clinical trial investigating early sacral nerve stimulation as an adjunct to standard neurogenic bladder management following acute spinal cord injury. *BMC Urol*. 2018;18:72.

101. Lotstein DS, Ghandour R, Cash A, McGuire E, Strickland B, Newacheck P. Planning for health care transitions: Results from the 2005-2006 National Survey of Children With Special Health Care Needs. *Pediatrics*. 2009;123:e145-152.
102. McManus MA, Pollack LR, Cooley WC, et al. Current status of transition preparation among youth with special needs in the United States. *Pediatrics*. 2013;131:1090-1097.
103. Ouyang L, Grosse SD, Armour BS, Waitzman NJ. Health care expenditures of children and adults with spina bifida in a privately insured U.S. population. *Birth Defects Res A Clin Mol Teratol*. 2007;79:552-558.
104. Grimsby GM, Burgess R, Culver S, Schlomer BJ, Jacobs MA. Barriers to transition in young adults with neurogenic bladder. *J Pediatr Urol*. 2016;12:258 e1-5.
105. Hettel D, Tran C, Szymanski K, Misseri R, Wood H. Lost in transition: Patient-identified barriers to adult urological spina bifida care. *J Pediatr Urol*. 2018;14:535 e1-e4.
106. Binks JA, Barden WS, Burke TA, Young NL. What do we really know about the transition to adult-centered health care? A focus on cerebral palsy and spina bifida. *Arch Phys Med Rehabil*. 2007;88:1064-1073.
107. Sawicki GS, Lukens-Bull K, Yin X, et al. Measuring the transition readiness of youth with special healthcare needs: Validation of the TRAQ-Transition Readiness Assessment Questionnaire. *J Pediatr Psychol*. 2011;36:160-171.
108. Jacobson LA, Tarazi RA, McCurdy MD, et al. The Kennedy Krieger Independence Scales-Spina Bifida Version: A measure of executive components of self-management. *Rehabil Psychol*. 2013;58:98-105.
109. Warschausky S, Kaufman JN, Schutt W, Evitts M, Hurvitz EA. Health self-management, transition readiness and adaptive behavior in persons with cerebral palsy or myelomeningocele. *Rehabil Psychol*. 2017;62:268-275.